Literature DB >> 25549347

Dynamic 18F-FDOPA PET Findings After Carbidopa Premedication in 2 Adult Patients With Insulinoma-Related Hyperinsulinemic Hypoglycemia.

Alessio Imperiale1, Thibault Bahougne, Bernard Goichot, Philippe Bachellier, David Taïeb, Izzie Jacques Namer.   

Abstract

(18)F-fluorodihydroxyphenylalanine (FDOPA) PET seems to be of limited value to localize pancreatic insulin-secreting tumors in adult with hyperinsulinemic hypoglycemia. Carbidopa is an efficient inhibitor of the peripheral aromatic amino acid decarboxylase, significantly reducing the physiological pancreatic FDOPA uptake. Nevertheless, carbidopa effect on FDOPA uptake in insulinomas is not fully elucidated. No final consensus has been reached about the usefulness of carbidopa in patients with insulinoma-related hyperinsulinemic hypoglycemia. Moreover, the ideal timing for PET/CT acquisitions is a matter of discussion. We report the results of dynamic FDOPA PET performed after carbidopa premedication in 2 adult patients with insulinoma.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25549347     DOI： 10.1097/RLU.0000000000000686

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  5 in total

Review 1.  Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

2.  Early 18F-FDOPA PET/CT imaging after carbidopa premedication as a valuable diagnostic option in patients with insulinoma.

Authors:  Benjamin Leroy-Freschini; Vincent Amodru; Pietro Addeo; Frédéric Sebag; Michel Vix; Laurent Brunaud; Marc Klein; Thibault Bahougne; Philippe Bachellier; Frédéric Castinetti; Bernard Goichot; Elodie Chevalier; David Taieb; Alessio Imperiale
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-07       Impact factor: 9.236

Review 3.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

4.  Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.

Authors:  Murat Fani Bozkurt; Irene Virgolini; Sona Balogova; Mohsen Beheshti; Domenico Rubello; Clemens Decristoforo; Valentina Ambrosini; Andreas Kjaer; Roberto Delgado-Bolton; Jolanta Kunikowska; Wim J G Oyen; Arturo Chiti; Francesco Giammarile; Anders Sundin; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-25       Impact factor: 9.236

Review 5.  Novel PET tracers: added value for endocrine disorders.

Authors:  Sébastien Bergeret; Judith Charbit; Catherine Ansquer; Géraldine Bera; Philippe Chanson; Charlotte Lussey-Lepoutre
Journal:  Endocrine       Date:  2019-03-14       Impact factor: 3.633
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.